Suppr超能文献

低剂量阿糖胞苷(LD-Ara C)治疗骨髓生成异常综合征(DMPS)和急性髓性白血病(AML)。

Low-dose cytosine arabinoside (LD-Ara C) treatment in dysmyelopoietic syndromes (DMPS) and acute myelogenous leukemia (AML).

作者信息

Jehn U, Göldel N, Vehling-Kaiser U

出版信息

Anticancer Res. 1987 May-Jun;7(3 Pt B):505-8.

PMID:3477124
Abstract

The effect of low-dose Ara C (LD-Ara C) (10 mg/m2 q 12 hr s.c.) for a minimum of 10 days was evaluated in 21 patients with acute myeloid leukemia (AML) and 15 patients with dysmyelopoietic syndromes (DMPS). Median age (range) for AML-patients was 47 yrs (19-89), and for DMPS-patients 60 (22-78). From the AML-group, 9 patients were either primary refractory or resistant to intensive re-induction treatment of relapse, 6 others had heavy pretreatment, 1 suffered from myelosclerosis. Five AML-patients had no pretreatment at first presentation and were started on LD-Ara C because of old age (3) or poor condition (2) including 1 patient with a secondary leukemia. DMPS included those with RAEB (8) and RAEB in transformation (7). 12 patients with AML and 4 with DMPS displayed a leukocytosis of greater than 10 X 10(9)/l. Three out of 21 AML-patients reached complete remission (CR), one of them twice, with partial remission (PR) at the third attempt with this type of treatment. Two other AML-patients reached a P.R. of 5 and 1 months duration respectively. Three patients experienced a transient response characterized by improved peripheral blood counts and cessation of transfusion requirements, one of them for 12 months. In 5 AML-patients no effect was seen and 8 pts. died. In the DMPS-group, 5/15 patients reached C.R., one patient twice with the same treatment, 1 patient reached a P.R., 1 improved, 6 showed no effect, and 2 died. In 13 patients final examination of the bone marrow was not performed after treatment because of either early death or obvious progression. Treatment was associated with significant, transient hematologic toxicity. Patients suffering from DMPS had prolonged aplasia and required more blood and platelet support than pts with AML. Responding leukemia patients had a rapid hematologic regeneration. Considering the poor prognosis of both of our treatment groups, this therapeutic approach proved to be of considerable benefit.

摘要

对21例急性髓系白血病(AML)患者和15例骨髓增生异常综合征(DMPS)患者评估了低剂量阿糖胞苷(LD-Ara C)(10 mg/m²,皮下注射,每12小时1次)至少使用10天的疗效。AML患者的中位年龄(范围)为47岁(19 - 89岁),DMPS患者为60岁(22 - 78岁)。在AML组中,9例患者对初次治疗难治或对复发后的强化再诱导治疗耐药,另外6例有重度预处理史,1例患有骨髓硬化症。5例AML患者初诊时未进行预处理,因年龄较大(3例)或病情较差(2例),包括1例继发性白血病患者,开始使用LD-Ara C治疗。DMPS包括难治性贫血伴原始细胞增多(RAEB)患者8例和转化中的RAEB患者7例。12例AML患者和4例DMPS患者白细胞计数高于10×10⁹/L。21例AML患者中有三例达到完全缓解(CR),其中一例达到两次,第三次尝试这种治疗时达到部分缓解(PR)。另外两名AML患者分别达到了持续5个月和1个月的PR。三名患者出现短暂反应,表现为外周血细胞计数改善和输血需求停止,其中一名患者持续了12个月。5例AML患者未见疗效,8例患者死亡。在DMPS组中,15例患者中有5例达到CR,一名患者通过相同治疗达到两次CR,1例患者达到PR,1例有所改善,6例无效果,2例死亡。13例患者因早期死亡或明显进展,治疗后未进行骨髓最终检查。治疗伴有显著的、短暂的血液学毒性。DMPS患者的再生障碍期延长,比AML患者需要更多的血液和血小板支持。有反应的白血病患者血液学再生迅速。考虑到我们两个治疗组的预后都很差,这种治疗方法被证明有相当大的益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验